Abstracts - faqs.org

Abstracts

Pharmaceuticals and cosmetics industries

Search abstracts:
Abstracts » Pharmaceuticals and cosmetics industries

SWITZERLAND: DADE BEHRING TO CLOSE UNIT

Article Abstract:

In June 2001 Chicago-based Dade Behring is to close immuno-haemotology unit in Dudingen, Switzerland. The unit serves the blood disease diagnostics and therapy sectors and is faced with markets with no notable growth. The move involves the reduction of workforce from 100 to 40. Until mid-2002 clients in Switzerland will be supplied by Dade-Behring's unit in Dortmund. The US company is concentrating on its core business of diagnostics systems.

Publisher: Vogt-Schild AG
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 2000
Drugs, Surgical and Medical Instrument Manufacturing, Surgical and medical instruments, Hematology Equipment, Dade Behring Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


SWITZERLAND: CHEMICAL FIBRE PRODUCER TO CLOSE DIVISIONS

Article Abstract:

Swiss chemical fibre producer Setila AG (former Viscosuisse), a subsidiary of French Setila S.A., will close its Nylon Polymerisation, Texturing and Spinning 2 divisions. The discontinuation will affect 48 staff. The Swiss producer will transfer yarn production to the Spinning 2 division and, for the time being, continue its polyester polymerisation division.

Publisher: Vogt-Schild AG
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 2001
Organic fibers, noncellulosic, Noncellulosic Organic Fiber Manufacturing, Synthetic Fibers

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


SWITZERLAND: OCTAPHARMA TO PROCESS BLOOD PLASMA

Article Abstract:

Octapharma AG of Ziegelbrucke, Switzerland, is to expand the blood plasma fractionating facilities and set up a R&D unit in a factory in Ligolsheim, eastern France, which it acquired from Centeon. In 1998 Octapharma generated a turnover of DM 202mn with blood plasma products. It has a production plant in Vienna.

Publisher: Vogt-Schild AG
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 1999
Research & development outlays, France, Expanded capacity, plant expansion, Ethical Preparations, Drugs, Octapharma

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Switzerland, Hematologic agents
Similar abstracts:
  • Abstracts: SWITZERLAND/UK: ROCHE/VERNALIS DEVELOPING TOGETHER. SWITZERLAND/US: CANCER R&D DEAL BY ROCHE, BMS. SWITZERLAND/UK: LONZA, CELLTECH COOPERATE
  • Abstracts: SWITZERLAND: NEW POLYAMIDE BY EMS-CHEMIE. SWITZERLAND: MADER EXPAND SYNTHETIC RESIN OUTPUT. SWITZERLAND: CREANOVA CONCENTRATES DISTRIBUTION
  • Abstracts: US/SWITZERLAND: ZELLER COOPERATES WITH SKB. SWITZERLAND/JAPAN: NATURAL COSMETICS BY WELEDA
  • Abstracts: SWITZERLAND: MADER EXPAND SYNTHETIC RESIN OUTPUT. GERMANY: BASF UPS GRANULE OUTPUT
  • Abstracts: EUROPE: BSE AND GELATINE MARKETS. SWITZERLAND: CIBA BOOSTS WATER TREATMENTS. SWITZERLAND/US: CYDEX TECHNOLOGY FOR PEPTICHEMIO
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.